| First Author | Lee B | Year | 2017 |
| Journal | JCI Insight | Volume | 2 |
| Issue | 7 | Pages | e90517 |
| PubMed ID | 28405613 | Mgi Jnum | J:320902 |
| Mgi Id | MGI:6863337 | Doi | 10.1172/jci.insight.90517 |
| Citation | Lee B, et al. (2017) RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis. JCI Insight 2(7):e90517 |
| abstractText | Osteolytic bone diseases, such as osteoporosis, are characterized by diminished bone quality and increased fracture risk. The therapeutic challenge remains to maintain bone homeostasis with a balance between osteoclast-mediated resorption and osteoblast-mediated formation. Osteoclasts are formed by the fusion of monocyte/macrophage-derived precursors. Here we report, to our knowledge for the first time, that receptor-interacting protein 140 (RIP140) expression in osteoclast precursors and its protein regulation are crucial for osteoclast differentiation, activity, and coupled bone formation. In mice, monocyte/macrophage-specific knockdown of RIP140 (mvarphiRIP140KD) resulted in a cancellous osteopenic phenotype with significantly increased bone resorption and reduced bone formation. Osteoclast precursors isolated from mvarphiRIP140KD mice had significantly increased differentiation potential. Furthermore, conditioned media from mvarphiRIP140KD primary osteoclast cultures significantly suppressed osteoblast differentiation. This suppressive activity was effectively and rapidly terminated by specific Syk-stimulated RIP140 protein degradation. Mechanistic analysis revealed that RIP140 functions primarily by inhibiting osteoclast differentiation through forming a transcription-suppressor complex with testicular receptor 4 (TR4) to repress osteoclastogenic genes. These data reveal that monocyte/macrophage RIP140/TR4 complexes may serve as a critical transcription regulatory complex maintaining homeostasis of osteoclast differentiation, activity, and coupling with osteoblast formation. Accordingly, we propose a potentially novel therapeutic strategy, specifically targeting osteoclast precursor RIP140 protein in osteolytic bone diseases. |
